The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Galectin-3: An open-ended story
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Boussac, M., Véron, P., Ricciardi-Castagnoli, P., Raposo, G., Garin, J., & Amigorena, S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.12.7309 · Cited by 1,563
Galectins as modulators of tumour progression
Liu, F.-T., & Rabinovich, G. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1527 · Cited by 1,439
Galectins: A family of animal β-galactoside-binding lectins
Barondes, S. H., Castronovo, V., Cooper, D. N. W., Cummings, R. D., Drickamer, K., Felzi, T., Gitt, M. A., Hirabayashi, J., Hughes, C., Kasai, K.-I., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90498-7 · Cited by 1,223
SMART 4.0: towards genomic data integration
Letunic, I. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh088 · Cited by 1,003
Sharma, U. C., Pokharel, S., van Brakel, T. J., van Berlo, J. H., Cleutjens, J. P. M., Schroen, B., André, S., Crijns, H. J. G. M., Gabius, H. J., Maessen, J., et al. (2004) · Circulation · doi:10.1161/01.cir.0000147181.65298.4d · Cited by 947
Oligosaccharide specificity of galectins: a search by frontal affinity chromatography
Hirabayashi, J., Hashidate, T., Arata, Y., Nishi, N., Nakamura, T., Hirashima, M., Urashima, T., Oka, T., Futai, M., Muller, W. E. G., et al. (2002) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00311-2 · Cited by 926
Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation
Demetriou, M., Granovsky, M., Quaggin, S., & Dennis, J. W. (2001) · Nature · doi:10.1038/35055582 · Cited by 901
Expression of galectin-3 modulates T-cell growth and apoptosis.
Yang, R. Y., Hsu, D. K., & Liu, F. T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.13.6737 · Cited by 789
Regulation of Cytokine Receptors by Golgi N-Glycan Processing and Endocytosis
Partridge, E. A., Le Roy, C., Di Guglielmo, G. M., Pawling, J., Cheung, P., Granovsky, M., Nabi, I. R., Wrana, J. L., & Dennis, J. W. (2004) · Science · doi:10.1126/science.1102109 · Cited by 735
Garin, J., Diez, R., Kieffer, S., Dermine, J.-F., Duclos, S., Gagnon, E., Sadoul, R., Rondeau, C., & Desjardins, M. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.1.165 · Cited by 684
Cited by
LAG 3 (CD 223) as a cancer immunotherapy target
Andrews, L. P., Marciscano, A. E., Drake, C. G., & Vignali, D. A. A. (2017) · Immunological Reviews · doi:10.1111/imr.12519 · Cited by 956
Kouo, T., Huang, L., Pucsek, A. B., Cao, M., Solt, S., Armstrong, T., & Jaffee, E. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0150 · Cited by 531
Galectin-3: A Novel Mediator of Heart Failure Development and Progression
de Boer, R. A., Voors, A. A., Muntendam, P., van Gilst, W. H., & van Veldhuisen, D. J. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp097 · Cited by 524
The regulation of inflammation by galectin‐3
Henderson, N. C., & Sethi, T. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00794.x · Cited by 522
Glycosylation: mechanisms, biological functions and clinical implications
He, M., Zhou, X., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01886-1 · Cited by 499
Lok, D. J. A., Van Der Meer, P., de la Porte, P. W. B.-A., Lipsic, E., Van Wijngaarden, J., Hillege, H. L., & van Veldhuisen, D. J. (2010) · Clinical Research in Cardiology · doi:10.1007/s00392-010-0125-y · Cited by 465
Biomarkers and diagnostics in heart failure
Gaggin, H. K., & Januzzi, J. L. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.12.014 · Cited by 423
Ronco, C., Cicoira, M., & McCullough, P. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.077 · Cited by 422
Stowell, S. R., Arthur, C. M., Mehta, P., Slanina, K. A., Blixt, O., Leffler, H., Smith, D. F., & Cummings, R. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709545200 · Cited by 418
Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)
Dong, R., Zhang, M., Hu, Q., Zheng, S., Soh, A., Zheng, Y., & Yuan, H. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3311 · Cited by 406
Alencar, G. F., Owsiany, K. M., Karnewar, S., Sukhavasi, K., Mocci, G., Nguyen, A. T., Williams, C. M., Shamsuzzaman, S., Mokry, M., Henderson, C. A., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046672 · Cited by 403
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Cai, L., Li, Y., Tan, J., Xu, L., & Li, Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01499-1 · Cited by 391
The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., & Chen, H. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.180 · Cited by 386
Xie, H., Vucetic, S., Iakoucheva, L. M., Oldfield, C. J., Dunker, A. K., Obradovic, Z., & Uversky, V. N. (2007) · Journal of Proteome Research · doi:10.1021/pr060394e · Cited by 382
Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor
Ruffo, E., Wu, R. C., Bruno, T. C., Workman, C. J., & Vignali, D. A. A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101305 · Cited by 381
“Gal-3 can be expressed on different cell types thus exerting its regulatory function on CD8+ T cells via multiple mechanisms [29].”
BackgroundGalectin-3, a marker for vacuole lysis by invasive pathogens
Paz, I., Sachse, M., Dupont, N., Mounier, J., Cederfur, C., Enninga, J., Leffler, H., Poirier, F., Prevost, M.-C., Lafont, F., et al. (2010) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01415.x · Cited by 381
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G., Bellotti, C., Salehi, L., & Ricci, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020379 · Cited by 377
The fibrosis marker galectin‐3 and outcome in the general population
de Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller Kobold, A. C., van Gilst, W. H., Hillege, H. L., Bakker, S. J. L., & van der Harst, P. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02476.x · Cited by 376
Galectin-3 – A jack-of-all-trades in cancer
Newlaczyl, A. U., & Yu, L.-G. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.003 · Cited by 362
Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis
Calvier, L., Miana, M., Reboul, P., Cachofeiro, V., Martinez-Martinez, E., de Boer, R. A., Poirier, F., Lacolley, P., Zannad, F., Rossignol, P., et al. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300569 · Cited by 359
Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks
Peixoto, A., Relvas-Santos, M., Azevedo, R., Santos, L. L., & Ferreira, J. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00380 · Cited by 334
Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers
Lakshminarayan, R., Wunder, C., Becken, U., Howes, M. T., Benzing, C., Arumugam, S., Sales, S., Ariotti, N., Chambon, V., Lamaze, C., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2970 · Cited by 321
Glycosylation in immune cell trafficking
Sperandio, M., Gleissner, C. A., & Ley, K. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00795.x · Cited by 310
Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update
Suthahar, N., Meijers, W. C., Silljé, H. H. W., Ho, J. E., Liu, F.-T., & de Boer, R. A. (2018) · Theranostics · doi:10.7150/thno.22196 · Cited by 309
Sato, S., St‐Pierre, C., Bhaumik, P., & Nieminen, J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00790.x · Cited by 299
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Sasidharan Nair, V., & Elkord, E. (2018) · Immunology & Cell Biology · doi:10.1111/imcb.1003 · Cited by 298
When Galectins Recognize Glycans: From Biochemistry to Physiology and Back Again
Di Lella, S., Sundblad, V., Cerliani, J. P., Guardia, C. M., Estrin, D. A., Vasta, G. R., & Rabinovich, G. A. (2011) · Biochemistry · doi:10.1021/bi201121m · Cited by 282
Sattiraju, A., Kang, S., Giotti, B., Chen, Z., Marallano, V. J., Brusco, C., Ramakrishnan, A., Shen, L., Tsankov, A. M., Hambardzumyan, D., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.017 · Cited by 279
The Many Roles of Galectin-3, a Multifaceted Molecule, in Innate Immune Responses against Pathogens
Díaz-Alvarez, L., & Ortega, E. (2017) · Mediators of Inflammation · doi:10.1155/2017/9247574 · Cited by 262
Bayes-Genis, A., de Antonio, M., Vila, J., Peñafiel, J., Galán, A., Barallat, J., Zamora, E., Urrutia, A., & Lupón, J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.087 · Cited by 259
Argüeso, P., Guzman-Aranguez, A., Mantelli, F., Cao, Z., Ricciuto, J., & Panjwani, N. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033332 · Cited by 257
Novel biomarkers for cardiovascular risk prediction.
Wang, J., Tan, G.-J., Han, L.-N., Bai, Y., He, M., & Liu, H. (2017) · PubMed · doi:10.11909/j.issn.1671-5411.2017.02.008 · Cited by 256
Stowell, S. R., Qian, Y., Karmakar, S., Koyama, N. S., Dias-Baruffi, M., Leffler, H., McEver, R. P., & Cummings, R. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3091 · Cited by 255
Structure, evolution, and biology of the MUC4 mucin
Chaturvedi, P., Singh, A. P., & Batra, S. K. (2008) · The FASEB Journal · doi:10.1096/fj.07-9673rev · Cited by 252
Cathepsins: Proteases that are vital for survival but can also be fatal
Patel, S., Homaei, A., El-Seedi, H. R., & Akhtar, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.148 · Cited by 224
“Galectin is a β-galactoside-binding, regulatory protein, with role in cell adhesion, cell cycle control, immunomodulation, and cancer progression [57].”
BackgroundHuo, J.-L., Wang, Y.-T., Fu, W.-J., Lu, N., & Liu, Z.-S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956090 · Cited by 176
Galectin-3 is a new MerTK-specific eat-me signal
Caberoy, N. B., Alvarado, G., Bigcas, J., & Li, W. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22955 · Cited by 176
Exosome Determinants of Physiological Aging and Age-Related Neurodegenerative Diseases
D’Anca, M., Fenoglio, C., Serpente, M., Arosio, B., Cesari, M., Scarpini, E. A., & Galimberti, D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00232 · Cited by 154
The therapeutic potential of galectin-3 inhibition in fibrotic disease
Slack, R. J., Mills, R., & Mackinnon, A. C. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105881 · Cited by 136
Rotshenker, S. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9186-7 · Cited by 111
Iacobini, C., Menini, S., Ricci, C., Scipioni, A., Sansoni, V., Cordone, S., Taurino, M., Serino, M., Marano, G., Federici, M., et al. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.186791 · Cited by 91
Galectin-3-Mediated Glial Crosstalk Drives Oligodendrocyte Differentiation and (Re)myelination
Thomas, L., & Pasquini, L. A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00297 · Cited by 76
Shi, L., Rocha, M., Zhang, W., Jiang, M., Li, S., Ye, Q., Hassan, S. H., Liu, L., Adair, M. N., Xu, J., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20925655 · Cited by 71
Galectin-3 Plays an Important Role in Innate Immunity to Gastric Infection by Helicobacter pylori
Park, A.-M., Hagiwara, S., Hsu, D. K., Liu, F.-T., & Yoshie, O. (2016) · Infection and Immunity · doi:10.1128/iai.01299-15 · Cited by 67
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Galectin-3 Modulates Th17 Responses by Regulating Dendritic Cell Cytokines
Fermin Lee, A., Chen, H.-Y., Wan, L., Wu, S.-Y., Yu, J.-S., Huang, A. C., Miaw, S.-C., Hsu, D. K., Wu-Hsieh, B. A., & Liu, F.-T. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.06.017 · Cited by 63
Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis
Al Attar, A., Antaramian, A., & Noureddin, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1894127 · Cited by 47
“and extracellular level allows it to exert its effects by binding to numerous partners and signaling molecules [22,23].”
BackgroundKing, D. R., Salako, D. C., Arthur-Bentil, S. K., Rubin, A. E., Italiya, J. B., Tan, J. S., Macris, D. G., Neely, H. K., Palka, J. M., Grodin, J. L., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.050 · Cited by 29
Galectin-3 in Microglia-Mediated Neuroinflammation: Implications for Central Nervous System Diseases
Tian, Y.-K., Ye, D.-W., Ge, M.-M., Chen, N., Zhou, Y.-Q., & Yang, H. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220201094547 · Cited by 31
Metadata
- Authors
- Dumic, J., Dabelic, S., & Flögel, M.
- Venue
- Biochimica et Biophysica Acta (BBA) - General Subjects
- Publisher
- Elsevier BV
- Published
- 2006-04
- Volume
- 1760
- Issue
- 4
- Pages
- 616-635
- ISSN
- 0304-4165 (ISSN-L)
- OpenAlex
- W2094188666
- Cited by
- 1,169
- References
- 173
- FWCI
- 14.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.